Join the dots or lose out, Syneos Health advises big pharma

pharmaphorum | May 30, 2019

Pharma companies need to rethink how they communicate and share information and insights within their own organisations, according to Syneos Health’s principal for real world and late phase development, Erwin De Cock. We spoke to him at the eyeforpharma conference in Barcelona to learn about the company’s Biopharmaceutical Acceleration Model, and the increasing importance of real-world evidence.It’s widely accepted across the pharma industry that there is a need to make organisations more agile and focused to be able to bring innovative products to patients in need.To achieve this goal, how can management better join their disparate business functions such as commercial operations and R&D that may well be outsourced, to make operations more efficient and get drugs to market faster?Erwin De Cock, principal for real world and late phase development at Syneos Health champions the company’s Biopharmaceutical Acceleration Model, an end-to-end concept that encourages cross-pollination across all functions throughout clinical and commercial.He told pharmaphorum at the eyeforpharma conference that the “slice and dice” model that is still so common across the industry needs to be revised in order to help decision making by improving communication across business functions working in silos.Instead, De Cock’s philosophy is focused on ensuring that various business functions improve communication around products in development with each other in order for the business to do better at achieving its strategic and commercial objectives.“It’s very much about getting people aligned internally by them talking to each other so that they all understand each other’s viewpoints and the data and evidence they want to see.While the separation between R&D/ clinical and commercial has been introduced historically in order to satisfy regulators, continuing to work in this way is holding back progress, he said.

Spotlight

Quantifying the direct and indirect value that a business unit delivers to its parent health system has traditionally been difficult. In this case study, we discuss the impact of pharmacy customer loyalty on the Fairview Health Services system, and we introduce a new, data-driven methodology for measuring value. Our approach utilizes external, individual-level consumer data and predictive modeling, and may be extensible to other health systems and service lines. Carrot Health analyzed the patient populations of Fairview (1.81 million patients) and its pharmacy division (415,000 customers).


Other News
BUSINESS INSIGHTS

Elligo Health Research® Partners With Peoples Rx

Elligo Health Research | April 21, 2022

Elligo Health Research, the largest healthcare-enabling research organization, announced they are expanding partnerships to include Peoples Rx, an Austin, Texas-based pharmacy chain. “We’re in a unique position at Peoples Rx to help inform more people about how they can participate in clinical research opportunities. Working with Elligo to offer research as healthcare to our customers helps support our mission to empower people to make educated health decisions.” Stephen Erickson, Peoples Rx president One of the first studies Peoples Rx will be working to share with Elligo is a study for people to advance screening diagnostics for cancer. “Our patients may not hear about clinical research opportunities otherwise, and this empowers patients with knowledge to become more proactive in their own healthcare journey while simultaneously supporting the advancement of health sciences,” Erickson said. Elligo began its mission to provide easy access to clinical research as care to more patients nearly six years ago. Specifically, Elligo is focused on accelerating clinical trials through healthcare by maintaining the integrity of the trusted patient and physician relationship, building local healthcare communities, and leveraging electronic health records. “Accomplishing this mission is made possible by the partnerships we have with real-world healthcare,” said Elligo CEO John Potthoff, Ph.D. “Peoples Rx has a positive impact on our local community and is a trusted partner for healthcare. This is also Elligo’s first partnership with a pharmacy, and it is our hope that this will lead to further opportunities to collaborate with more providers in the healthcare spectrum on similar initiatives and continue contributing to the changing clinical research landscape.” About Elligo Health Research® Elligo Health Research accelerates clinical trials through healthcare with access to known patients and their HIPAA-compliant healthcare data, our IntElligo® Research Stack technology, and our hybrid enrollment model, PatientSelect. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. About Peoples Rx Peoples Rx has been the local favorite pharmacy and wellness headquarters in Austin for over 40 years. Our integrative approach to health and wellness starts with our knowledgeable and experienced pharmacists and wellness specialists, and our cutting-edge, holistic, and professional products. We also compound custom medications in our state-of-the-art lab to meet customers’ specific needs. And because food is medicine too, our own in-house delis serve up scratch-made meals and snacks with the highest quality ingredients. With a mission to empower people to make educated health choices, several of our 170+ employees, including clinical nutritionists, herbalists, naturopaths, and homeopaths also offer their expertise through private consultations and educational events.

Read More

BUSINESS INSIGHTS

Pack4U acquires leading pharmacy technology company Catalyst Healthcare

Pack4U | January 07, 2022

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited about building the next phase of Pack4U with the Catalyst team on board. Catalyst's proprietary and patented platform strengthens our ability to meet the needs of patients, providers and health plans by offering a full, end-to-end, connected care solution seamlessly integrated with our vast clinical team across all states." Pack4U President, Rahul Chopra Pack4U provides in-home and virtual services that connect patients with pharmacists for oversight, medication delivery, remote monitoring, and care coordination. Our complete suite of connected health IP fortifies Pack4U's ability to personalize care, improve health outcomes, and lower total cost of care across North America. "I am extremely excited to see these organizations come together and to join the team that is transforming in-home healthcare," said Shane Bishop. "Pack4U's extensive and diverse team of pharmacists combined with Catalyst's adherence solutions, create opportunity for a new patient monitoring paradigm. With central fills for scale and community pharmacy adoption, we will reach more people to change more lives." "This collaboration follows our aggressive growth in 2021. It expands our vision of in-home care via a full suite of managed services featuring patient specific, in-home medicine dispensing, always-on patient engagement, electronic medicine administration record and supply chain software for centralized filling," said Rahul Chopra. About Pack4U Pack4U Inc is a tech-enabled health services company. We connect people with community pharmacists to manage drug complexity and maximize health benefits through personalized medication delivery, virtual monitoring, and proactive care. Our fully automated, high-volume central fill pharmacy hubs, proprietary health platform and medication adherence network power a robust, scalable solution to chronic condition management that leads to better patient outcomes and total cost of care reduction.

Read More

BUSINESS INSIGHTS

The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine

Lifebit Biotech | April 29, 2022

Lifebit, whose leading technology enables secure analysis over sensitive datasets for researchers and interconnects such large patient cohorts worldwide, today announces a long-term partnership with the Danish National Genome Center (NGC). Lifebit will deploy Lifebit CloudOS to create a Federated Trusted Research Environment within the Danish NGC's supercomputing cluster to serve as the scalable and secure data management and analysis platform for Denmark's national researchers, clinical scientists and international collaborators. The Danish NGC, a government agency and authority within the Danish Healthcare system, was created to implement the Danish Government's National Personalised Medicine Strategy. The core vision of the NGC is to develop more precise diagnosis, targeted treatment and strengthen research within the Danish healthcare system. During the first phase of the strategy, the Danish National Genome Center and its collaborators will recruit and sequence whole genomes of 60,000 patients diagnosed with cancer, autoimmune disorders and rare diseases by 2024. The platform will deliver a next-generation computational infrastructure within Denmark's on-premise supercomputing center, allowing the NGC to meet its vision of establishing and operating a state-of-the-art national infrastructure for personalised medicine while keeping the data at all times in the secure national infrastructure. Only Lifebit with both its genomic data expertise as well as its internationally proven ability of managing such complex Government environments through its patented operating system Lifebit CloudOS was deemed capable to deliver this project. The platform will thus enable researchers with secure access, querying and analysis of this sensitive clinico-genomic data in a fully scalable and flexible way; also allowing for them to collaborate at a global scale. Federation will play a crucial role in enabling the future possibility to collaborate with international partners such as Genomics England, France Genomique, Genomic Medicine Sweden and other biobanks from around the world. Virtually connecting these sensitive datasets, enabling joint analysis that is however performed in situ without moving data, can lead to exponentially higher research findings. In some cases, it can be observed that increasing the number of patients in a study by 10x led to ~100x the number of scientific findings and genomic associations making clear how important real connectivity of these datasets is. "Lifebit continues to guide and power the world's largest national and private precision medicine programmes. We are extremely proud to be delivering this flagship programme for the nation of Denmark. This Federated Trusted Research Environment will enable researchers to more effectively collaborate over this rich dataset at scale and drive international collaboration between other government initiatives - many of which already leverage Lifebit's federated technology." Thorben Seeger, Chief Business Development Officer at Lifebit Other examples of Lifebit's data platform at work include Genomics England, NIHR Cambridge and the Hong Kong Genome Institute. About Lifebit Biotech, Ltd. Lifebit builds enterprise data platforms for use by organisations with complex and sensitive biomedical datasets. Lifebit's patented federated technology securely unlocks access to biomedical data. From providing Trusted Research Environments for national precision medicine programmes to enabling pharmaceutical companies to discover new drug targets faster, Lifebit empowers customers to transform how they leverage sensitive biomedical data.

Read More

PHARMACY MARKET

DrFirst Pharmacy Solution Earns Edison Award for Excellence in Commercial Technology, Consumer Safety

DrFirst | April 26, 2022

DrFirst's SmartSuite for Pharmacy has earned a prestigious Bronze Edison Award in the Commercial Technology, Consumer Safety Category, honoring the solution's innovative use of artificial intelligence to improve safety for patients and efficiency for pharmacies. The Edison Awards is a global leader in recognizing and honoring the best in innovation and excellence in the development of new products and services to create a positive impact on the world. "Being recognized with an Edison Award is one of the highest accolades a company can receive for innovation in product development and business. We deeply appreciate this recognition for SmartSuite for Pharmacy, which also highlights the dangers posed by medication errors and the need to provide more accurate, efficient technology solutions to hard-working pharmacists." G. Cameron Deemer, president at DrFirs SmartSuite for Pharmacy cleans and accurately translates medication data between incompatible systems, which saves time and can help reduce adverse drug events—the cause of more than 100,000 deaths per year. "The Edison Awards is delighted to recognize DrFirst for its innovation and positive impact on patients and health systems throughout the U.S. with SmartSuite for Pharmacy," said Frank Bonafila, executive director of Edison Awards. This year's Edison Awards finalists were chosen by senior business executives and academics from across the globe, whose votes acknowledge excellence in meeting the award criteria. The awards are named for Thomas Alva Edison, whose extraordinary contributions garnered 1,093 U.S. patents, pioneered multiple industries, and made him a household name worldwide. The 2022 Edison Awards were celebrated April 20 to 22, 2022, in Fort Myers, Florida, at an event hosted by award-winning science and technology journalist Miles O'Brien of PBS NewsHour. SmartSuite for Pharmacy is an AI-powered solution that cross-links an electronic prescription from a provider's EHR to an actual product on the shelf at the receiving pharmacy. It also translates abbreviated medication directions from the electronic prescription into the specific "short codes" used by the receiving pharmacy. Finally, SmartSuite for Pharmacy codifies allergy data for safety checks within the pharmacy workflow. About The Edison Awards The Edison Awards is an annual competition designed to honor excellence in new product and service development, marketing, human-centered design and innovation. Winners represent "game changing" products, services and excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact. Started in 1987, The Awards are named after inventor Thomas A. Edison and symbolize the persistence and excellence in innovation personified by him. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including more than 120,000 prescribers, 70,000 pharmacies, 280 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.

Read More

Spotlight

Quantifying the direct and indirect value that a business unit delivers to its parent health system has traditionally been difficult. In this case study, we discuss the impact of pharmacy customer loyalty on the Fairview Health Services system, and we introduce a new, data-driven methodology for measuring value. Our approach utilizes external, individual-level consumer data and predictive modeling, and may be extensible to other health systems and service lines. Carrot Health analyzed the patient populations of Fairview (1.81 million patients) and its pharmacy division (415,000 customers).

Resources